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Spinal and bulbar muscular atrophy (SBMA) is an X-linked motoneuron disease caused by an abnormal
expansion of a tandem CAG repeat in exon 1 of the androgen receptor (AR) gene that results in an
abnormally long polyglutamine tract (polyQ) in the AR protein. As a result, the mutant AR (ARpolyQ)
misfolds, forming cytoplasmic and nuclear aggregates in the affected neurons. Neurotoxicity only ap-
pears to be associated with the formation of nuclear aggregates. Thus, improved ARpolyQ cytoplasmic
clearance, which indirectly decreases ARpolyQ nuclear accumulation, has beneﬁcial effects on affected
motoneurons. In addition, increased ARpolyQ clearance contributes to maintenance of motoneuron
proteostasis and viability, preventing the blockage of the proteasome and autophagy pathways that
might play a role in the neuropathy in SBMA. The expression of heat shock protein B8 (HspB8), a member
of the small heat shock protein family, is highly induced in surviving motoneurons of patients affected by
motoneuron diseases, where it seems to participate in the stress response aimed at cell protection. We
report here that HspB8 facilitates the autophagic removal of misfolded aggregating species of ARpolyQ.
In addition, though HspB8 does not inﬂuence p62 and LC3 (two key autophagic molecules) expression, it
does prevent p62 bodies formation, and restores the normal autophagic ﬂux in these cells. Interestingly,
trehalose, a well-known autophagy stimulator, induces HspB8 expression, suggesting that HspB8 might
act as one of the molecular mediators of the proautophagic activity of trehalose. Collectively, these data
support the hypothesis that treatments aimed at restoring a normal autophagic ﬂux that result in the
more efﬁcient clearance of mutant ARpolyQ might produce beneﬁcial effects in SBMA patients.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
Spinal and bulbar muscular atrophy (SBMA) is an X-linked
neuromuscular disease characterized by the loss of motoneurons in
the spinal cord and in the bulbar regions of the brain stem.
Degeneration of sensory neurons in the dorsal root ganglia has also
been reported. SBMA is the result of a CAG triplet repeat expansion
in the androgen receptor (AR) gene (La Spada et al., 1991) thated Endocrinologia, Diparti-
eB), Universita’ degli Studi di
9 02 5031 8215; fax: þ39 02
.
r Inc. Open access under CC BY licenseresults in an elongated polyglutamine (polyQ) tract in the N-ter-
minal transactivation domain of the mutant AR protein (ARpolyQ).
In unaffected individuals, the polyQ tract ranges in size from 9 to 37
Qs, and polyQ expansions that extend longer than 38 contiguous Qs
lead to neuronal toxicity that is the cause of motoneuron death in
SBMA. Eight other inherited neurodegenerative diseases have been
found to be the result of similar elongated polyQ tracts and are
classiﬁed as CAG/polyQ-diseases (Orr and Zoghbi, 2007; Pennuto
et al., 2009). In each disease, the elongated polyQ tract is believed
to act through a gain-of-function mechanism by inducing the for-
mation of an aberrant protein conformation. This leads to protein
misfolding and aggregation, and ultimately neuronal toxicity
(motoneuronal in the case of SBMA). The fact that AR is an
extremely well characterized member of the steroid receptor su-
perfamily (Poletti, 2004; Vismara et al., 2009) makes SBMA a
valuable model to study CAG/polyQ-related diseases because it al-
lows for the discrimination between the physiological and.
P. Rusmini et al. / Neurobiology of Aging 34 (2013) 2585e26032586pathological activities of ARpolyQ. In addition, ARpolyQ toxicity
strictly depends on the binding of the receptor to androgens
(Chevalier-Larsen et al., 2004; Fischbeck, 2012; Katsuno et al.,
2003a, 2012; Schmidt et al., 2002), which apparently converts
ARpolyQ from a non-pathological to a pathological status (Katsuno
et al., 2003a, 2003b), possibly via the induction of conformational
changes in the mutant protein. These alterations could be linked to
the release of accessory chaperones and/or to the AR nuclear
translocation, because both processes have been linked to ARpolyQ
neurotoxicity. Incorrect ARpolyQ folding during its activation re-
sults in the formation of nuclear aggregates in anterior horn spinal
cord motoneurons and cytoplasmic aggregates in dorsal root
ganglia (Adachi et al., 2005; Suzuki et al., 2008). Nuclear localiza-
tion, but not aggregation, is apparently required for ARpolyQ
neurotoxicity (Montie et al., 2009, 2011). In fact, cytoplasmic
retention of ARpolyQ correlates with a decrease in its toxicity
(Montie et al., 2009, 2011). However, non-nuclear ARpolyQ
neurotoxic mechanisms have also been described (Morﬁni et al.,
2006; Piccioni et al., 2002; Ranganathan et al., 2009; Schindler
et al., 2012); for instance, misfolded cytoplasmic ARpolyQ can
trigger a Bax-dependent apoptotic pathway (Young et al., 2009). In
our motoneuronal SBMA models, testosterone induces the forma-
tion of cytoplasmic ARpolyQ aggregates (Simeoni et al., 2000) that
we have already shown do not correlate with increased cell death
(Rusmini et al., 2007; Simeoni et al., 2000). We postulated that, at
least in the early stages of their formation, cytoplasmic ARpolyQ
aggregation contributes to segregate the harmful proteins into
physically deﬁned intracellular compartments (Carra et al., 2012).
At later stages, however, these aggregates might themselves
become toxic because they might affect other cellular activities
(e.g., protein clearance, axonal transport) that might also
contribute to neurotoxicity (Piccioni et al., 2002; Poletti, 2004;
Rusmini et al., 2010).
Apart from their role in neurotoxicity, aggregates represent a
valuable “marker of misfolding” because their presence clearly
correlates with defects in the misfolded protein clearance via
proteolytic pathways (both the ubiquitin-proteasome system
[UPS] or autophagy) (Carra et al., 2012; Rusmini et al., 2010, 2011;
Sau et al., 2011). Indeed, cytoplasmic soluble ARpolyQ (testos-
terone-untreated) has been shown to impair UPS activity
(Rusmini et al., 2007) because it might overwhelm its degrada-
tive capacity. In addition, it has been shown that the UPS poorly
degrades long polyQs (Holmberg et al., 2004). Interestingly,
ARpolyQ aggregation (induced by testosterone) correlates with
UPS desaturation (Rusmini et al., 2007). In addition, ARpolyQ
(with or without testosterone) activates autophagy (Rusmini
et al., 2010) and autophagic inhibition increases ARpolyQ ag-
gregation (Rusmini et al., 2010). Thus, cytoplasmic ARpolyQ ag-
gregation might depend on autophagic ﬂux failure (Rusmini
et al., 2010) so that the stimulation of autophagy would have
beneﬁcial effects.
We recently showed that the small heat shock protein B8
(HspB8) facilitates autophagic removal of other proteins associ-
ated with motoneuron diseases (e.g., SOD1 and TDP-43) (Carra
et al., 2012; Crippa et al., 2010a, 2010b). Moreover, it has been
already shown that HspB8 exerts antiaggregation and/or prode-
gradative activity on ARpolyQ, but so far this has been evaluated
only on the AR nontoxic conformational status (without testos-
terone) (Carra et al., 2005). Here, we evaluated and compared the
HspB8 activities on ARpolyQ clearance in the presence and
absence of testosterone and found that HspB8 restores the
normal autophagic ﬂux in motoneuronal cells expressing ARpo-
lyQ (with or without testosterone). Interestingly, we also found
that the trehalose proautophagic activity might be mediated by
HspB8 action.2. Methods
Chemicals, 3-methyladenine (3-MA), MG132, and trehalose
were obtained from Sigma-Aldrich (St Louis, MO, USA).
2.1. Plasmids
The plasmids AR.Q23 and AR.Q46, routinely used in our labora-
tory, have beenpreviously described (Simeoni et al., 2000). The GFP-
AR.Q22 andGFP-AR.Q48were obtained by insertion of AR cDNA into
the green ﬂuorescent protein (GFP) vector, expressing chimeric
ﬂuorescent fusion proteins as previously described (Stenoien et al.,
1999). The plasmid pCNEO-cMyc-HspB8 expressing themyc tagged-
rat HspB8 was obtained from J. Landry, Université Laval, Québec,
Canada (Chavez Zobel et al., 2003) and the plasmid pCI-HspB8
contains the sequence of human HspB8 cloned in pCI (Promega,
Madison,WI, USA) (Carra et al., 2005). The plasmidGFPu, expressing
a proteasome activity reporter based on aGFP fused to a constitutive
degradation signal (CL-1), was obtained from Ron Kopito, Stanford
University, Stanford, CA, USA (Bence et al., 2001). The plasmid
pmRFP-LC3, expressing the autophagic reporter LC3 tagged with
mRFP, was obtained from Aviva Tolkovsky, University of Cambridge,
UK (Klionsky et al., 2012). The plasmid pDest-mCherry-p62,
expressing a Cherry-tagged p62, was obtained from Terje Johansen,
University of Tromsø, Norway (Pankiv et al., 2007). pDsRed-mono-
mer-C1 encodes amonomericmutant form of the Discosoma sp. Red
ﬂuorescent protein DsRed (Clontech Laboratories, Inc, Mountain
View, CA, USA). The plasmid promB8 expresses the ﬁreﬂy luciferase
gene under the control of the human HspB8 promoter (Crippa et al.,
2010b). pRL-TK was from Promega. To silence LC3 expression we
used an shRNA construct againstMus MusculusMap1LC3b in pGFP-
V-RS-vector and a scrambled noneffective shRNA, as control (Ori-
Gene Technologies, Inc, Rockville, MD, USA), as previously described
(Rusmini et al., 2011).
To silence endogenous HspB8 expression we used a custom
siRNA duplex (CGG AAG AGC UGA UGG UAA AUU) (Dharmacon,
Thermo Scientiﬁc Life Sciences Research, Waltham, MA, USA).
2.2. Cell cultures and transfections
The immortalized motoneuron cell line, NSC34 (Cashman et al.,
1992), is routinely used in our laboratory (Crippa et al., 2010a,
2010b; Piccioni et al., 2001; Rusmini et al., 2011; Simeoni et al.,
2000), and was transfected with lipofectamine (Invitrogen, Life
Technologies Corporation, Carlsbad, CA, USA) and transferrin
(Sigma-Aldrich), as previously described (Marron et al., 2005;
Simeoni et al., 2000) using 1.0e1.5 mg of plasmid DNA, 3 mL of
transferrin solution and 2 mL of lipofectamine.
HspB8 and scramble siRNA were transfected using Lipofecta-
mine 2000 (Invitrogen) according to themanufacturers’ instructions.
In the experiments involving steroid hormone treatments, the
fetal bovine serum (FBS) was replaced with charcoal stripped-FBS, to
eliminate endogenous steroids (Poletti et al., 2001; Pozzi et al., 2003).
The following amounts of cDNAs were used: (1) 0.5 mg of
AR.Q(n) or GFP-AR.Q(n); (2) 0.6 mg of pCNEO-cMyc-HspB8,
pCIHspB8 or pCDNA3 as vector control; (3) 0.05 mg of GFPu; (4) 0.2
mg of DsRed Monomer; (5) 0.2 mg of mRFP-LC3; (6) 0.2 mg of
mCherry-p62; (7) 0.5 mg of shRNA against LC3 or shRNA scrambled
control; (8) 0.25 mg of promB8; and (9) 0.25 mg of pRL-TK.
2.3. Fluorescence, immunoﬂuorescence, and microscopy on NSC34
cells
NSC34 cells were plated in 12-well multiwell plates containing
coverslips at a density of 70,000 cells per well and transiently
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for 48 hours and then ﬁxed and processed as previously described
(Sau et al., 2007). To analyze AR.Q(n), HspB8, LC3, and p62, we used
the following primary antibodies: rabbit polyclonal AR (H280)
(Santa Cruz Biotech, SantaCruz, CA, USA) 1:100 in milk, rabbit
polyclonal anti-HspB8 antibody 1:400 in 3% BSA Tween-TBS (TBS-T,
20 mM TrisHCl, pH 7.5, 0.5 M NaCl, 0.05% Tween-20) (Carra et al.,
2005), rabbit polyclonal anti-LC3-B antibody 1:1000 (Sigma-
Aldrich) in milk, rabbit polyclonal anti-SQSTM1/p62 antibody
1:1000 (Abcam, Cambridge, UK) in milk. Secondary antibodies used
were: Alexa 488 anti-rabbit and Alexa 594 anti-rabbit (Invitrogen)
1:1000 in milk. Cells were stained with DAPI to visualize the nuclei.
An Axiovert 200 microscope (Zeiss, Oberkochen, Germany) equip-
ped with FITC/TRITC/DAPI and combined with a Photometric Cool-
Snap CCD camera (Ropper Scientiﬁc, Trenton, NJ, USA) was used.
Images were processed using Metamorph software, version 7.7.7.0
(Universal Imaging, Downingtown, PA, USA).
GFP-AR.Q48 transfected cells bearing aggregates were estimated
using a PL 10X/20 eyepiece with graticules (100 mm  10 mm in
100-grid divisions). The percentage of cells presenting GFP-AR.Q48
cytoplasmic aggregates was divided by the total number of the
transfected DsRed-monomer positive cells. At least 150 cells per
ﬁeld were counted, and 3 ﬁelds for each coverslip were analyzed.
The experiments were performed in triplicate.
2.4. Western blot analysis and ﬁlter retardation assay
For Western blot (WB) analysis and ﬁlter retardation assay
(FRA), NSC34 cells were plated in 12-wellmultiwell plates at 80,000
cells per well and transfected as previously described.
After 48 hours from transfection, cells were harvested and
centrifuged for 5 minutes at 100g at 4 C; the cell pellets were
resuspended in phosphate buffered saline (added to the protease
inhibitor cocktail; Sigma-Aldrich) and homogenized using slight
sonication as previously described (Poletti et al., 2001). Total pro-
teins were determined with the bicinchoninic acid method (BCA
assay, Euroclone). WB analysis was performed on 15% sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis loading
30 mg of total proteins. Samples were then electrotransferred to
PVDF (Polyscreen transfer membrane, PerkinElmer, Watham, MA,
USA) using a liquid transfer apparatus (Bio-Rad, Hercules, CA, USA).
The membranes were treated with a blocking solution containing
5% nonfat driedmilk powder (EuroClone, Pero, Milan, Italy) in TBS-T
for 1 hour and then incubated with the primary antibodies: (1)
rabbit polyclonal AR-H280 (dilution 1:1000) to detect wild type
(wt) AR and ARpolyQ; (2) rabbit polyclonal anti-LC3 (dilution
1:1000) to detect the LC3; (3) rabbit polyclonal anti-SQSTM1/p62
(dilution 1:1000) to detect p62; (4) goat polyclonal anti-actin (Actin
I-19; Santa Cruz Biotech, dilution 1:1000) to detect total actin; (5)
mouse monoclonal anti-a-tubulin (Sigma-Aldrich, dilution 1:1000)
to detect total a-tubulin; (6) home-made rabbit polyclonal anti-
HspB8 (kindly provided by Dr Jacques Landry, Quèbec, Canada,
dilution 1:1000 in 3% BSA TBS-T); and (7) peroxidase labeled
anti-GFP (Vector Laboratories; dilution 1:5000) to detect GFPu.
Immunoreactivity was detected using the following secondary
peroxidase-conjugated antibodies: goat anti-rabbit (sc-2004, Santa
Cruz Biotech, dilution 1:5000) was used to identify the anti-AR, the
anti-HspB8, the anti-LC3, and the anti-p62 antibody; donkey anti-
goat (sc-2020, Santa Cruz Biotech, dilution 1:5000) was used to
identify the anti-actin antibody; goat anti-mouse (sc-2005, Santa
Cruz Biotech, dilution 1:5000) was used to identify the anti-a-
tubulin antibody. The immunoreactive regionswere then visualized
using the enhanced chemiluminescence detection kit reagents (ECL
prime Western Blotting Substrate, GE Healthcare). The same
membranes were subsequently processed with different antibodiesto detect the levels of different proteins in the same sample loaded
on the gel, after stripping for 10 minutes at room temperature
(StripABlot, EuroClone).
FRA was performed using sample ﬁltration through a 0.2-mm
cellulose acetate membrane (Whatman, GE Healthcare, Maidstone,
UK) using a dot-blot apparatus (Bio-Rad) and loading 1.5 mg of total
proteins for AR.Q(n). Dot-blots were probed as described for WB
analysis.
A ChemiDoc XRS System (Bio-Rad) was used for the image
acquisition of WB and FRA.
Optical intensity of samples assayed with WB or FRA was
detected and analyzed using NIH ImageJ software.2.5. Cytoﬂuorimetric analysis
Samples for cytoﬂuorimetric analysis were obtained fromNSC34
cells plated in 12-well multiwell plates at a density of 90,000 cells
per well. The cells, transfected as described earlier in text, were
harvested and centrifuged for 5 minutes at 100g at 4 C. The pellets
were resuspended in 300 mL of 4% FBS phosphate buffered saline.
Cell ﬂuorescence was detected using FACS Calibur (BD Biosciences,
San Jose, CA, USA). Cytoﬂuorimetric results were analyzed using
CellQuest (BD Biosciences) analysis software.2.6. Messenger RNA expression analysis
NSC34 were plated at 80,000 cells per mL in 6-well multiwell
plates and were transfected as described earlier in text.
Forty-eight hours from transfection, cells were harvested in 4 M
guanidium-isothiocyanate (containing 25 mM sodium citrate pH
7.5, 0.5% sarcosyl and 0.1% 2-mercaptoethanol) and total RNA was
isolated using phenol-chloroform extraction according to
Chomczynski and Sacchi (1987). RNA quantiﬁcationwas carried out
by absorption at 260 nm. Total RNA (1 mg) was treated with DNAse
and reverse transcribed into cDNA using the High-Capacity cDNA
Archive Kit (Applied Biosystems, Life Technologies Corporation,
Carlsbad, CA, USA) according to the manufacturer’s protocol.
Primers for real-time reverse transcription polymerase chain re-
action (PCR) of the HspB8, LC3-B, p62, and GAPDHmessenger RNAs
(mRNAs) were designed in accordance with recommendations
accompanying the CFX 96 Real Time System (Bio-Rad) on C-G base
content and 5’ content and using the program Primer Express 3. The
primers were synthesized by MWG Biotech (Ebersberg, Germany)
with the following sequence: mHspB8: 5’-ATACGTGGAAGTTT-
CAGGCA-30 (forward), 5’- TCCTTTGACCTAACGCAACC-30 (reverse);
mMAP-LC3b: 50- CGT CCT GGA CAA GAC CA-30 (forward), 50-CCA TTC
ACC AGGAGGAA-30 (reverse);mp62: 50-AGG GAACAC AGC AAG CT-
30 (forward), 50-GCC AAA GTG TCC ATG TTT CA-30 (reverse);
mGAPDH: 50-CCA GAA CAT CAT CCC TGC AT -30 (forward), 50-CAG
TGA GCT TCC CGT TCA-30 (reverse). The evaluated efﬁciency of each
set of primers was close to 100% for target and reference genes.
Real-time PCR was performed using the CFX 96 Real Time System
(Bio-Rad) in 10 mL total volume, using the iTaq SYBR Green Super-
mix (Bio-Rad), and with 500 nM primers. PCR cycling conditions
were as follows: 94 C for 10 minutes, 35 cycles at 94 C for 15
seconds and 60 C for 1 minute. Melting curve analysis was always
performed at the end of each PCR assay as a control for speciﬁcity.
Data were expressed as Ct values and used for the relative quanti-
ﬁcation of targets using the DDCt calculation. To exclude potential
bias because of averaging datawere transformed using the equation
2DDCt to give N-fold changes in gene expression; all statistics were
performed with DCt values. Each experiment was carried out using
4 independent samples. HspB8, LC3, and p62 values were then
normalized with those of GAPDH.
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For promB8 transcriptional activity, cells were plated at 80,000
cells per mL in 24-well multiwell plates and were transfected with
promB8 and pRL-TK plasmids as described earlier in text. Starting
from the day of transfection, cells were treated with trehalose 100
mM. Forty-eight hours after transfection, transcriptional assay was
performed using the Dual-Glo Luciferase Assay System (Promega)
as previously described (Crippa et al., 2010b).
2.8. Statistical analysis
Statistical analysis was performed using 1-tailed Student t test
for 2-group comparisons and 2-way ANOVA for 3 or more group
comparisons using PRISM software, version 5.0a (GraphPad Soft-
ware, La Jolla, CA, USA).
3. Results
To determine whether HspB8 counteracts ARpolyQ accumula-
tion by facilitating its clearance and whether a possible link with
testosterone AR activation might occur, we evaluated the levels
of soluble and aggregated forms of ARpolyQ after HspB8
overexpression.
3.1. Effect of HspB8 on ARpolyQ biochemical behavior during
testosterone activation
We have previously shown that HspB8 overexpression increases
the clearance of mutant ARpolyQ in cells that are not treated with
its ligand, testosterone (Carra et al., 2005). However, the aggrega-
tion properties of ARpolyQ change depending on the absence or
presence of testosterone. We thus measured the levels of solubleFig. 1. Effect of heat shock protein (Hsp)B8 on wild type (wt) and mutant androgen recept
clearance. (A) Western blot analysis on cell lysates of NSC34 expressing wt AR (AR.Q23) or m
of 10 nM of T for 48 hours. a-tubulin was used to normalize protein loading. (B) Western blo
absence (T) or in the presence (þT) of 10 nM of T for 48 hours. b-actin was used to normali
monomer, GFP-AR.Q22, or GFP-AR.Q48, pCDNA3, or HspB8 in the absence (T) or in the pres
T-untreated controls;  p < 0.01 vs. GFP-AR.Q48T; xx p < 0.01 vs. GFP-AR.Q48þT). (D) F
pCDNA3, or HspB8 in the absence (T) or in the presence (þT) of 10 nM of T for 48 hou
testosterone; pCDNA3, empty vector.and aggregated forms of ARpolyQ in cells overexpressing HspB8
either in absence or presence of testosterone. As shown in Fig.1A, in
our immortalized motoneuronal model of SBMA, HspB8 over-
expression reduced the levels of monomeric SDS-soluble ARpolyQ
(AR.Q46) in the absence and presence of testosterone, and the effect
of HspB8 on wt AR (AR.Q23) was negligible. The ARpolyQ can exist
as SDS-soluble monomers, higher molecular weight (HMW) homo-
and/or heteromers and aggregates (Merry et al., 1998), the latter
being not readily detectable using WB analysis. In addition, low but
signiﬁcant amounts of fragmented ARs can also be formed (Merry
et al., 1998), hardly quantiﬁable in WB (unless WB is overexposed,
see an example in Fig. 1B; see also WB obtained with untagged
ARpolyQ, later in text). We thus developed a cytoﬂuorimetric assay
to quantify the effect of HspB8 on different ARpolyQ forms,
measuring all chimeric fragmented GFP-AR (N-terminally tagged
GFP-AR fragments) and full-length species containing the polyQ
and including also insoluble material. Fig. 1C shows that though
testosterone treatment did not affect the levels of wt AR (GFP-
AR.Q22), it leads to a strong accumulation of the mutant ARpolyQ
form (GFP-AR.Q48), which was signiﬁcantly reverted by the coex-
pression of HspB8.
The strong effect exerted by HspB8 speciﬁcally on the mutant
ARpolyQ might reveal a speciﬁcity of HspB8 to aggregate-prone
species by recognizing and clearing both and/or either HMWand/or
aggregated AR species. In fact, inclusions formation is a complex
and dynamic multistep process. Soluble misfolded species must
interact together to form intermediate and insoluble species. At a
speciﬁc time point, soon after testosterone-induced activation (and
release from protective Hsps) these species exist in a “soluble and
dynamic,” but already aggregated status (Simeoni et al., 2000;
Stenoien et al., 1999, 2002), and are believed to protect against
mutant protein toxicity (Rusmini et al., 2007, 2011). Indeed, using
FRA, in which HMW ARpolyQ species can be retained andor (AR) gene with an abnormally long polyglutamine tract (ARpolyQ) aggregation and
utant ARpolyQ (AR.Q46), pCDNA3 or HspB8 in the absence (T) or in the presence (þT)
t analysis performed on NSC34 cells transfected with GFP-AR.Q22 or GFP-AR.Q48, in the
ze protein loading. (C) Cytoﬂuorimetric analysis performed on NSC34 expressing DsRed
ence (þT) of 10 nM of T for 48 hours (* p < 0.05 vs. T-untreated controls; ** p < 0.01 vs.
ilter retardation assay performed on NSC34 cells transfected with AR.Q23 or AR.Q46,
rs (** p < 0.01 vs. T-untreated controls; xx p < 0.01 vs. AR.Q46þT). Abbreviations: T,
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reduced the total amount of ARpolyQ (AR.Q46) insoluble species
formed after testosterone treatment (Fig. 1D). To conﬁrm the
speciﬁcity of the HspB8 prodegradative effects on misfolded
ARpolyQ, we downregulated HspB8 expression with a speciﬁc
siRNA and, using FRA, quantiﬁed the levels of misfolded ARpolyQ-
insoluble species. HspB8 silencing correlated with a robust accu-
mulation of testosterone-treated ARpolyQ insoluble species (see
below), while, as expected, the control scramble siRNA had no effect
on insoluble ARpolyQ. Thus, even if HspB8 basal expression levels
are low in NSC34 cells (Crippa et al., 2010b), this endogenous
concentration of HspB8 is already sufﬁcient to remove a large
relevant, but not the entire fraction, of misfolded ARpolyQ-insol-
uble species present in these cells. This provides an explanation for
the ARpolyQ accumulation into aggregates after testosterone
treatment. The higher protein levels achievable with exogenous
HspB8 overexpression, thus allow this chaperone to fully clear
misfolded ARpolyQ-insoluble species, preventing ARpolyQ
aggregation.
We also analyzed, using “high resolution ﬂuorescence micro-
scopy,” the intracellular distribution of wt and mutant AR in the
absence and presence of testosterone and/or HspB8. Though wt AR
(GFP-AR.Q22) showed no aggregates either in the absence or
presence of testosterone, testosterone treatment induced cyto-
plasmic ARpolyQ inclusions (GFP-AR.Q48) in 12.69% ( 0.96) of our
immortalized motoneurons (Fig. 2) (Rusmini et al., 2007, 2011;
Simeoni et al., 2000). HspB8 reduced aggregate formation, and
only 6.98% ( 0.72; p < 0.01) of transfected cells were aggregate-
positive (Fig. 2) in linewith the data obtained with FRA on insoluble
ARpolyQ (Fig. 1D). Interestingly, an inverse correlation was noted
between HspB8 expression levels and ARpolyQ accumulation,
suggestive of an increased HspB8-mediated clearance of GFP-
AR.Q48 (see arrows in the lower insets of Fig. 2). Notably, HspB8 had
no effect onwt AR (GFP-AR.Q22), supporting the notion that HspB8
only mildly affects the non-pathological and non-aggregate-prone
AR forms (either ARpolyQ non-activated with testosterone or the
wt AR in any condition), and signiﬁcantly inhibits the aggregation
and accumulation of the pathologic ones.
3.2. Effect of HspB8 on ARpolyQ-induced alterations of the
proteasome pathway
As mentioned, our published data demonstrated that soluble
(testosterone-untreated) ARpolyQ overwhelms UPS activity, and
aggregated ARpolyQ (testosterone-treated) allows UPS desatura-
tion (Rusmini et al., 2007). Thus HspB8, by preventing ARpolyQ
aggregation, could indirectly increase the pool of soluble ARpolyQ
species that are routed to UPS degradation and could overwhelm
it. To test this hypothesis, UPS function was evaluated in the
absence and presence of HspB8 by monitoring the degradation of
the UPS reporter protein GFPu (Bence et al., 2001), which accu-
mulates when UPS is impaired (Rusmini et al., 2007; Sau et al.,
2007). The cytoﬂuorimetric assay conﬁrmed that (Fig. 3A) GFPu
accumulated only in motoneuronal cells expressing soluble
ARpolyQ (AR.Q46), and testosterone-induced ARpolyQ aggrega-
tion correlated with increased GFPu clearance, as an index of
restored UPS activity. HspB8 coexpression with ARpolyQ (with or
without testosterone) always correlated with increased GFPu
removal from motoneuronal cells (Fig. 3A) demonstrating that the
antiaggregation activity of HspB8 on ARpolyQ does not alter UPS
functions.
WB (Fig. 3B, upper insets) and immunoﬂuorescence (Fig. 3C)
analyses conﬁrmed that GFPu accumulates in basal condition.
Indeed, analyzing UPS activity in single cells expressing ARpolyQ
(soluble or aggregated), we found that cells in which testosterone-activated ARpolyQ was still present did not show aggregates indi-
cating a pronounced clearance mediated by HspB8; here, no GFPu
accumulation was detectable (Fig. 3C).
In addition, we investigated the effects of HspB8 when UPS ac-
tivity is pharmacologically inhibited by the proteasome inhibitor,
MG132. In FRA, we found that even when UPS is inactivated, HspB8
greatly reduced (even if not completely) the accumulation of mis-
folded ARpolyQ-insoluble species (Fig. 3B, lower insets). Notably,
we found an inverse stabilization of ARpolyQ after testosterone
treatment with or without UPS inhibition. Indeed, as shown in WB
analysis, with unblocked UPS, testosterone increased ARpolyQ
levels (Piccioni et al., 2002; Rusmini et al., 2007, 2010, 2011;
Simeoni et al., 2000). When the UPS is inhibited, untreated ARpo-
lyQ accumulated at very high levels, conﬁrming its preferential
degradation via UPS. Conversely, the testosterone-treated ARpolyQ
(mainly composed of misfolded insoluble species) does not un-
dergo the same increase and/or stabilization, possibly because
misfolded ARpolyQ uses alternative degradative pathways, such as
the autophagic system. However, basal autophagy does not
completely remove ARpolyQ, which accumulates into intracellular
aggregates. Because misfolded ARpolyQ insoluble species almost
completely disappear in the presence of HspB8 when UPS is
blocked, we evaluated the possibility that the HspB8 prode-
gradative activity has to be due to autophagy.
3.3. Involvement of the autophagic pathway in the HspB8-mediated
clearance of ARpolyQ
The UPS is typically counterbalanced by the autophagic system.
A regulatory cross-talk exists between the two systems, to maintain
a proper balance in intracellular protein homeostasis (Gamerdinger
et al., 2011a, 2011b). We have shown that UPS is impaired by the
expression of ARpolyQ per se. As a consequence of UPS impairment,
cells expressing mutant ARpolyQ would need to preferentially
target it to autophagy degradation. HspB8 overexpression might
thus assist in this autophagy-targeting step. In fact, we previously
published that HspB8, in association with the cochaperone BAG-3,
leads to autophagy-mediated degradation of other aggregate-prone
misfolded proteins (Carra et al., 2008a, 2008b; Crippa et al., 2010a,
2010b). Using cytoﬂuorimetric analysis we studied the effect of
HspB8 on the autophagy-mediated clearance of GFP-AR.Q48
(normalized by dsRED monomer). We ﬁrst conﬁrmed that ARpolyQ
is degraded by autophagy (Fig. 4A). As expected, treatment with 3-
MA, an autophagy inhibitor that prevents autophagosome forma-
tion at very early stages (Klionsky et al., 2012; Rubinsztein et al.,
2009), led to the accumulation of a large ARpolyQ fraction (in the
presence or absence of testosterone treatment). Similarly, accu-
mulation of mutant ARpolyQ was observed in cells expressing
HspB8 and treated with 3-MA, showing that HspB8 requires auto-
phagy to exert its antiaggregation and/or prodegradative effects.
These data were also in line with the data obtained using FRA
(Fig. 4B), which demonstrated that autophagy inhibition correlated
with a lack of HspB8 effect on the clearance of testosterone-induced
misfolded ARpolyQ-insoluble species retained by the cellulose ac-
etate membrane.
We next analyzed whether and/or how HspB8 modulates the
autophagy system to remove aggregates from motoneuronal cells.
We evaluated autophagy activation using two well-known
markers: LC3 and p62 (Klionsky et al., 2012). LC3 exists in two
forms: LC3-I, which has a diffuse cytoplasmic distribution, and
lipidated LC3-II, which is recruited to the membrane of the auto-
phagosome allowing their formation (Klionsky et al., 2012). p62 is a
protein that recognizes and/or binds to (poly)ubiquitinated sub-
strates and also interacts with LC3, thus allowing substrate tar-
geting to autophagosomes (Klionsky et al., 2012). Both proteins are
Fig. 2. Effect of heat shock protein (Hsp)B8 on aggregation and intracellular distribution of wild type (wt) and mutant androgen receptor (AR) gene with an abnormally long
polyglutamine tract (ARpolyQ). High resolution immunoﬂuorescence microscopy analysis (magniﬁcation 63) on NSC34 cells transfected with GFP-AR.Q22 or GFP-ARQ.48 (green),
pCDNA3 or HspB8 (red) in the absence (T) or in the presence (þT) of 10 nM of T for 48 hours. Nuclei were stained with DAPI (blue) (scale bar, 10 mm). Abbreviations: DAPI,
40 ,6-diamidino-2-phenylindole; pCDNA3, empty vector; T, testosterone.
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the autophagic ﬂux is impaired (Klionsky et al., 2012; Rubinsztein
et al., 2009). Moreover, their protein levels are tightly transcrip-
tionally controlled, thus their rate of synthesis is inﬂuenced by the
rate of their clearance via autophagy. In particular, when autophagic
ﬂux is insufﬁcient (or impaired), p62 (normally diffused into the
cytoplasm) accumulates into the so called “p62 bodies” which
are capable of triggering aberrant pathways inside the cells(Matsumoto et al., 2011). To monitor the autophagic process we
thus analyzed LC3 and p62 mRNA and protein levels and their
subcellular distribution in cells expressing mutant ARpolyQ and/or
HspB8, in the absence and presence of speciﬁc autophagy inhibitors
(Klionsky et al., 2012). We ﬁrst analyzed LC3-I to LC3-II conversion
and p62 levels in NSC34 cells not expressing AR (either wt or
mutant). As shown in Fig. 4C, we failed to detect p62 accumulation
or LC3 activation either in the absence or presence of testosterone,
Fig. 3. .The antiaggregation/prodegradative activity of heat shock protein (Hsp)B8 on androgen receptor (AR) gene with an abnormally long polyglutamine tract (ARpolyQ) does not
require the ubiquitin proteasome system. (A) Cytoﬂuorimetric analysis performed on NSC34 cells expressing GFPu, DsRed monomer, AR.Q23 or AR.Q46, pCDNA3, or HspB8 in the
absence (T) or in the presence (þT) of 10 nM of T for 48 hours (*** p < 0.001 vs. T-untreated controls;  p < 0.001 vs. AR.Q23T; xx p < 0.01 vs. AR.Q23þT; ### p < 0.001 vs.
AR.Q46T; ^^^ p < 0.001 vs. AR.Q46þT;  p < 0.01 vs. AR.Q23T). (B) Upper insets, Western blot analysis, and lower insets, ﬁlter retardation assay, on cell lysates of NSC34 cells
expressing GFPu, AR.Q46, pCDNA3, or HspB8 in the absence (T) or in the presence (þT) of 10 nM of T for 48 hours, in basal condition or after treatment with 10 mM of MG132 for 24
hours. a-Tubulin was used to normalize protein loading. ( p < 0.01 vs. T-untreated controls; ** p < 0.01 vs. T-treated controls; * p < 0.05 vs. T-treated controls; # p < 0.05 vs. T/
þMG132; xx p < 0.01 vs. þT/þMG132). (C) High resolution immunoﬂuorescence analysis of NSC34 cells transfected with GFPu, AR.Q46, pCDNA3, or HspB8 in the absence (T) or in
the presence (þT) of 10 nM of T for 48 hours. Nuclei were stained with DAPI (blue). Images were obtained at magniﬁcation 63 (scale bar, 10 mm). Abbreviations: DAPI, 4,6-
diamidino-2-phenylindole; GFPu, green ﬂuorescent protein fused to a constitutive degron signal, CL1; MG132, Z-leu-leu-leu-al; pCDNA3, empty vector; T, testosterone.
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basically activated. However, a mild increase of p62 was present in
NSC34 cells expressing wt AR (a protein with a slight tendency to
misfold), and a robust increase of p62 was detectable in NSC34
cells expressing mutant ARpolyQ (which has a great tendency to
misfold), paralleled by a slight increase in LC3-II levels. We next
evaluated the possible effect of HspB8 on autophagic ﬂux. We
followed endogenous LC3-II/LC3-I dynamic and p62 levels,
particularly when autophagy was pharmacologically blocked with
3-MA, because LC3-II and p62 usually undergo a rapid degradation
via autophagy. The WB (Fig. 4D) indicates that endogenous LC3-I
levels remained substantially unchanged in all basal conditions
tested. As expected, an increase of LC3-I was evident during
autophagy ﬂux blockage with 3-MA. This 3eMA-dependent in-
crease in LC3-I levels is related to inhibition of its turnover via
autophagolysosomes. Interestingly, in testosterone-treated NSC34
cells expressing ARpolyQ, HspB8 overexpression resulted in a
slight, but signiﬁcant reduction of LC3-II/LC3-I ratio when
compared with HspB8 untransfected cells (see quantiﬁcation in
Fig. 4E); no signiﬁcant variations were observed in the case of
testosterone-untreated cells (no ARpolyQ aggregation). In the
presence of 3-MA, which inhibits autophagosome formation thus
inducing LC3-II accumulation, we found no effects of HspB8 on the
LC3-II/LC3-I ratio (Fig. 4E).
Because increased LC3-II levels observed on ARpolyQ over-
expression could be because of ﬂux blockage (Klionsky et al., 2012),
rather than increased production of LC3 (Klionsky et al., 2012;
Onesto et al., 2011), we also analyzed variations on p62 dynamic
induced by mutant ARpolyQ and the effects of HspB8 on these
parameters. Notably, p62 levels were found robustly increased in
the presence of mutant ARpolyQ and 3-MA (Fig. 4D, and quantiﬁ-
cation in Fig. 4F). As expected, in the absence of HspB8, autophagyblockage resulted in a larger increase of p62 accumulation in cells
treated with testosterone, when aggregates are generated; in fact,
in absence of testosterone, ARpolyQ is soluble and mainly pro-
cessed via the UPS (in agreement with the data presented in Fig. 3),
thus p62 levels are less affected. In the case of HspB8 over-
expression, we found a slight decrease in p62 levels with or without
testosterone, suggesting that HspB8 seems to reroute p62 degra-
dation via UPS.
As mentioned earlier in text, steady-state LC3 and p62 levels and
LC3-II/LC3-I ratio are consequence of the ﬁnal equilibrium of pro-
tein synthesis and clearance, which are both affected by autophagy
activation and autophagy ﬂux blockage. Thus, to corroborate our
working hypothesis of an HspB8 proautophagic degradative activity
on mutated ARpolyQ, we further analyzed the localization of the
exogenous LC3 and p62 in our experimental conditions (according
to the widely accepted guidelines on autophagy markers usage;
Klionsky et al., 2012).
The analysis of exogenous LC3 (mRFP-LC3) intracellular dis-
tribution is shown in Fig. 5A. It appears that, in nontransfected
NSC34 cells (either with or without testosterone) autophagy is
not activated; in fact exogenous mRFP-LC3 shows a diffused
intracellular distribution (in line with WB data shown in Fig. 4C).
A slight autophagy activation could be observed in NSC34 cells
expressing wt GFP-AR.Q22 (either with or without testosterone),
because mRFP-LC3 clearance appears higher than that measured
in the absence of AR protein (as already mentioned, it is very well
known that even wt AR has a tendency to generate few misfolded
species (Marcelli et al., 2006; Palazzolo et al., 2008; Piccioni et al.,
2001, 2002; Poletti, 2004; Rusmini et al., 2007, 2010, 2011;
Simeoni et al., 2000; Stenoien et al., 1999)), but most of the
remaining LC3 protein still presents a diffuse distribution. Inter-
estingly, a very similar condition could be found in NSC34 cells
Fig. 4. Active autophagy is required to mediate the antiaggregation and/or prodegradative activity of heat shock protein (Hsp)B8 on the androgen receptor (AR) gene with an
abnormally long polyglutamine tract (ARpolyQ). (A) Cytoﬂuorimetric analysis performed on NSC34 cells expressing DsRed monomer, GFP-AR.Q48, pCDNA3, or HspB8 in the absence
(T) or in the presence (þT) of 10 nM of T for 48 hours, in basal condition or after treatment with 10 mM of 3-methyladenine (3-MA) for 24 hours (** p < 0.01 vs. T-untreated
controls;  p < 0.01 vs. GFP-AR.Q48T; xx p < 0.01 vs. GFP-AR.Q48þT; ## p < 0.01 vs. GFP-AR.Q48þTþHspB8). (B) Filter retardation assay performed on NSC34 cells transfected
with AR.Q46, pCDNA3, or HspB8 in the absence (T) or in the presence (þT) of 10 nM of T for 48 hours, in basal condition or after treatment with 10 mM of 3-MA for 24 hours (* p <
0.05 vs. T-untreated controls; ** p < 0.01 vs. T-untreated controls;  p < 0.01 vs. AR.Q46T; x p < 0.05 vs. AR.Q46þT; ^^ p < 0.01 vs. AR.Q46þTþHspB8). (C) Western blot analysis on
cell lysates of NSC34 cells untrasfected (NT) or expressing AR.Q23 or AR.Q46, in the absence (T) or in the presence (þT) of 10 nM of T for 48 hours. b-actin was used to normalize
protein loading. (D) Western blot analysis on cell lysates of NSC34 cells expressing AR.Q46, pCDNA3 or HspB8 in the absence (T) or in the presence (þT) of 10 nM of T for 48 hours,
in basal condition or after treatment with 10 mM of 3-MA for 24 hours. b-actin was used to normalize protein loading. (E) The histogram represents a quantitative evaluation of LC3-
II/LC3-I ratio protein level carried out by densitometric scanning of the blots (3 replicates) ( p < 0.01 vs. AR.Q46T; x < 0.05 vs. AR.Q46þT; xx p < 0.01 vs. AR.Q46þT; # p < 0.05 vs.
AR.Q46TþHspB8; ^^ p < 0.005 vs. AR.Q46þTþHspB8). (F) The histogram represents a quantitative evaluation of p62 protein level normalized on actin carried out by densitometric
scanning of the blots (3 replicates) ( p < 0.01 vs. AR.Q46T; xx p < 0.01 vs. AR.Q46þT; ** p < 0.01 vs. T-untreated controls; ## p < 0.01 vs. AR.Q46TþHspB8; ^^ p < 0.01 vs.
AR.Q46þTþHspB8). Abbreviations: pCDNA3, empty vector; T, testosterone.
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absence of testosterone, in its nontoxic conformations. On the
contrary, ARpolyQ treated with testosterone, (neurotoxic and/or
aggregated species), induces a marked alteration of intracellular
mRFP-LC3 localization, which becomes clearly detectable in its
punctate distribution (lipidated LC3-II, indicative of autophagy
activation, but not necessarily of autophagic ﬂux completion).However, in these experiments (and the other performed
analyzing the endogenous LC3-II, see below) we observed neither
LC3-II/ARpolyQ colocalization nor LC3-II sequestration into
ARpolyQ aggregates. This demonstrates that aggregated ARpolyQ
is not entrapped in newly formed autophagosomes (not yet fused
to lysosome), thus suggesting an impairment of its recruitment
within these structures.
Fig. 5. Autophagy is activated by the presence of androgen receptor (AR) gene with an abnormally long polyglutamine tract (ARpolyQ), but not by heat shock protein (Hsp)B8. (A)
High-resolution ﬂuorescence microscopy analysis (magniﬁcation 63) on NSC34 cells expressing mRFP-LC3, and pCDNA3, GFP-AR.Q22 or GFP-AR.Q48 (/þHspB8), in the absence
(T) or in the presence (þT) of 10 nM of T. Nuclei were stained with DAPI (blue) (scale bar, 10 mm). (B) High-resolution ﬂuorescence microscopy analysis (magniﬁcation 63) on
NSC34 cells expressing mCherry-p62 and pCDNA3, GFP-AR.Q22 or GFP-AR.Q48 (/þHspB8) in the absence (T) or in the presence (þT) of 10 nM of T. Nuclei were stained with DAPI
(blue) (scale bar, 10 mm). Abbreviations: Ctrl, control; DAPI, 40 ,6-diamidino-2-phenylindole; GFP, green ﬂuorescent protein; mRFP-LC3, monomeric red ﬂuorescent protein; pCDNA3,
empty vector; T, testosterone.
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distribution of exogenous mCherry-p62 in NSC34 under various
conditions. Testosterone alone has no effect on p62 levels and
distribution (in line with WB data shown in Fig. 4C). Only a minor
increase of p62 ﬂuorescence, but no alteration in distribution,
was observed in NSC34 cells expressing wt AR (GFP-AR.Q22,
either in the absence or presence of testosterone). In contrast,
and in line with the data obtained with LC3, a marked p62
accumulation was evident in cells expressing mutant ARpolyQ
(GFP-AR.Q48), particularly in those treated with testosterone.
Notably, p62 tends to generate a large number of large p62
bodies, which often surrounded the ARpolyQ aggregates present
in our motoneuronal cells. Finally, the data in Fig. 5B show that
p62 accumulation (and ARpolyQ aggregation) can be counter-
acted by HspB8 expression, in line with the data obtained on LC3-
II formation (see Fig. 5A).
In light of these data we wanted to further unravel the mecha-
nism of action of HspB8. For this purpose, we deeply analyzed the
intracellular regulation of LC3 and p62. Fig. 6A shows a cyto-
ﬂuorimetric analysis that clearly demonstrates a robust LC3 accu-
mulation when proteasome or autophagy are pharmacologically
blocked with selective inhibitors. By contrast, exogenous LC3 levels
signiﬁcantly decreased in motoneuronal cells coexpressing mutant
ARpolyQ and HspB8. To discriminate between LC3 variation
because of (1) its de novo transcription; and (2) its clearance
(Klionsky et al., 2012; Rubinsztein et al., 2009), we also evaluated
whether LC3 transcription is induced in the presence of ARpolyQand/or HspB8. In fact, LC3 expression usually increases when
autophagy needs to be upregulated (i.e., autophagic ﬂux blockage).
Surprisingly, LC3 mRNA levels were similar in NSC34 cells
expressing ARpolyQ either in absence or presence of testosterone
(Fig. 6B), suggesting that the UPS function modiﬁcations that occur
in the presence of ARpolyQ with or without testosterone (see Fig. 3)
are not sufﬁcient to affect LC3 expression. Instead, after coex-
pression of HspB8, we found that in NSC34 cells expressing soluble,
nonactivated ARpolyQ (AR.Q46 without testosterone, in which UPS
functions are overwhelmed; see Fig. 3A) LC3 transcription was
increased. Conversely, in NSC34 cells in which ARpolyQ tends to
aggregate (testosterone-activated AR.Q46 and normal UPS activity),
HspB8 not only prevented ARpolyQ aggregation, but signiﬁcantly
reduced LC3 mRNA expression to levels lower than that found in its
testosterone-untreated control and in the absence of HspB8
(Fig. 6B). Interestingly, HspB8 alone does not induce LC3 mRNA
expression (see later in text, and Fig. 7B and C). Thus, when mis-
folded ARpolyQ fraction cannot accumulate and is rapidly cleared
from motoneuronal cells (see Fig. 1), the autophagic ﬂux proceeds
to completion, and LC3 levels decrease. This further supports the
notion that HspB8 acts by ameliorating the autophagic removal of
misfolded proteins rather than by directly activating autophagy
(Carra et al., 2012; Crippa et al., 2010a, 2010b).
Together these data on endogenous LC3 mRNA levels and
exogenous mRFP-LC3 strongly suggest that HspB8 efﬁciently con-
tributes to target mutant ARpolyQ to autophagy, thus restoring a
functional autophagic ﬂux.
Fig. 6. Autophagic ﬂux is impaired by the mutant androgen receptor (AR) gene with an abnormally long polyglutamine tract (ARpolyQ) and restored by heat shock protein (Hsp)B8.
(A) Cytoﬂuorimetric analysis performed on NSC34 cells expressing mRFP-LC3, GFP-AR.Q48, pCDNA3, or HspB8 in the absence (T) or in the presence (þT) of 10 nM of T for 48 hours,
in basal condition or after treatment with 10 mM of MG132 or 10 mM of 3-methyladenine (3-MA) for 24 hours ( p < 0.01 vs. GFP-AR.Q48T; xx p < 0.01 vs. GFP-AR.Q48þT). (B)
Real-time polymerase chain reaction (PCR) on LC3B mRNA expression levels on NSC34 cells expressing AR.Q46, pCDNA3, or HspB8 in the absence (T) or in the presence (þT) of 10
nM of T for 48 hours ( p < 0.01 vs. AR.Q46T; * p < 0.05 vs. AR.Q46þT). (C) Top insets, Western blot analysis of cell lysates of NSC34 cells expressing AR.Q46, pCDNA3, or HspB8 and
shRNA against LC3B or shRNA scrambled control in the absence (T) or in the presence (þT) of 10 nM of T for 48 hours. a-Tubulin was used to normalize protein loading. Bottom
inset, real time PCR on LC3B mRNA levels on NSC34 cells expressing shRNA-LC3B or shRNA-control. Data (expressed as fold changes) have been normalized to the amount of GAPDH
mRNA, and are expressed as relative to the levels determined in shRNA-control transfected cells, which are taken as internal reference. Data are mean  SD of 4 independent
replicates. (D) Cytoﬂuorimetric analysis performed on NSC34 expressing mCherry-p62, GFP-AR.Q48, pCDNA3, or HspB8 in the absence (T) or in the presence (þT) of 10 nM of T for
48 hours, in basal condition or after treatment with 10 mM of MG132 or 10 mM of 3-MA for 24 hours (*** p < 0.001 vs. T-untreated controls;  p < 0.01 vs. GFP-AR.Q48T; x p < 0.05
vs. GFP-AR.Q48þT; xxx p < 0.001 vs. GFP-AR.Q48þT). (E) Real-time PCR on p62 mRNA expression levels on NSC34 cells expressing AR.Q46, pCDNA3, or HspB8 in the absence (T) or
in the presence (þT) of 10 nM of T for 48 hours ( p < 0.01 vs. AR.Q46T; * p < 0.05 vs. AR.Q46TþHspB8). (F) High resolution immunoﬂuorescence analysis on NSC34 cells
transfected with GFP-AR.Q48 in the absence (T) or in the presence (þT) of 10 nM of T or 100 nM of cyproterone acetate or 100 nM of casodex for 48 hours. Nuclei were stained with
DAPI (blue). Images were obtained at magniﬁcation 63 (scale bar, 10 mm). Abbreviations: DAPI, 40 ,6-diamidino-2-phenylindole; GAPDH, glyceraldehyde-3-phosphate dehydro-
genase; MG132, Z-leu-leu-leu-al; mRFP-LC3, monomeric red ﬂuorescent protein-LC3; mRNA, messenger RNA; pCDNA3, empty vector; shRNA, short hairpin RNA; T, testosterone.
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ciﬁc shRNA. ShRNA effects were estimated using real-time PCR
analysis showing that LC3 levels were reduced to almost a fourth
(Fig. 6; approximately 75% reduction in the LC3 expression levels).
LC3 silencing completely abolished the HspB8 prodegradative ef-
fects on ARpolyQ (AR.Q46) thus proving that HspB8 requires a
functional autophagy to exert its protective antiaggregation and/or
prodegradative functions.
Finally, to evaluate whether HspB8 exerts this “facilitator ac-
tivity” on autophagy at very earlier stages (i.e., before misfolded
protein insertion into autophagosomes), we analyzed mRNA level
and protein distribution of p62. This protein acts in the very early
stages of autophagic ﬂux, because it recognizes ubiquitinated
misfolded substrates, releasing them to autophagosomes.
As already mentioned, like LC3, endogenous p62 protein levels
are also transcriptionally controlled and inﬂuenced by the rate of
p62 protein clearance via autophagy. We then measured exogenous
p62 levels (mCherry-p62), which are not transcriptionally inﬂu-
enced, but only affected by turnover (Klionsky et al., 2012). As
shown in Fig. 6D, we found a considerable reduction of exogenous
p62 when ARpolyQ was activated by testosterone. Proteasome in-
hibition has no major effect on p62 accumulation, and autophagyinhibition increased p62 accumulation. In contrast, HspB8 coex-
pression with ARpolyQ reduced exogenous p62 levels, in the
absence and in the presence of testosterone.
Expression analysis (Fig. 6E) revealed that endogenous p62
mRNA levels increased in NSC34 cells overexpressing nonactivated
ARpolyQ (AR.Q46) and HspB8, but decreased in the presence of
testosterone-activated ARpolyQ and HspB8, in line with the data on
endogenous LC3 mRNA expression and the permissive role of
HspB8 on autophagy.
In the case of p62, when autophagic ﬂux is insufﬁcient (or
impaired), p62 relocalizes accumulating into p62 bodies. We thus
also analyzed the endogenous p62 protein distribution in the
presence of ARpolyQ with or without testosterone (Fig. 6F). p62
distribution was affected by ARpolyQ independently of testos-
terone. In addition, p62 bodies did not colocalize with (or
sequester) the nonactivated (soluble) ARpolyQ, and, a tight
interaction between p62 bodies and testosterone-induced
ARpolyQ aggregates was present. Of note, the two aggregated
proteins remained physically independent (no cosegregation),
suggesting that the recognition process of misfolded ARpolyQ by
p62 is correctly initiated and the autophagic process started (see
data on LC3 distribution and lipidation). We thus might postulate
Fig. 7. Trehalose induces the clearance of mutant androgen receptor (AR) gene with an abnormally long polyglutamine tract (ARpolyQ), via autophagy activation. (A) Filter
retardation assay performed on NSC34 cells transfected with AR.Q46 in the absence (T) or in the presence (þT) of 10 nM of T for 48 hours, in basal condition or after treatment with
100 mM of trehalose for 48 hours (** p < 0.01 vs. T-untreated control; xx p < 0.01 vs. AR.Q46þT). (B) Real-time polymerase chain reaction (PCR) on LC3B mRNA expression levels on
NSC34 cells expressing pCDNA3 or heat shock protein (Hsp)B8 in basal condition or after treatment with 100 mM of trehalose for 48 hours (** p < 0.01 vs. untreated control). (C)
Upper insets, Western blot analysis of cell lysates of NSC34 expressing pCDNA3 or HspB8 in basal condition or after treatment with 100 mM of trehalose for 48 hours. b-actin was
used to normalize protein loading. Lower inset, the histogram represents a quantitative evaluation of LC3-II/LC3-I ratio protein level carried out by densitometric scanning of the
blots (3 replicates) (* p < 0.05 vs. untreated control). (D) Real-time PCR on LC3B mRNA expression levels on NSC34 cells expressing AR.Q46 in the absence (T) or in the presence
(þT) of 10 nM of T for 48 hours, in basal condition or after treatment with 100 mM of trehalose for 48 hours ( p < 0.01 vs. AR.Q46T; ## p < 0.01 vs. AR.Q46þT). (E) Real-time PCR
of p62 mRNA expression levels on NSC34 cells expressing AR.Q46 in the absence (T) or in the presence (þT) of 10 nM of T for 48 hours, in basal condition or after the treatment
with 100 mM of trehalose for 48 hours ( p < 0.01 vs. AR.Q46T; ## p < 0.01 vs. AR.Q46þT). (F) Filter retardation assay performed on cell lysates of NSC34 cells expressing AR.Q46,
in the absence (T) or in the presence (þT) of 10 nM of T for 48 hours, in basal condition or after treatment with 10 mM of 3-MA or 100 mM of trehalose for 24 hours. ( p < 0.05 and
 p < 0.01 vs. AR.Q46T; * p < 0.05 and ** p < 0.01 vs. AR.Q46þT; ## p < 0.01 vs. AR.Q46T/þtrehalose; xx p < 0.01 vs. AR.Q46þT/þtrehalose). Abbreviations: mRNA, messenger
RNA; pCDNA3, empty vector; T, testosterone.
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incomplete autophagic ﬂux impaired at initial stages, before
ARpolyQ insertion into autophagosomes, because ARpolyQ
inclusion did not colocalize with or sequester LC3-II. Interest-
ingly, ARpolyQ aggregates and/or p62 bodies were not present in
cells overexpressing HspB8 (see Fig. 5B), and ARpolyQ levels were
very low.
To gain further information on the relevance of p62 bodies
formation in ARpolyQ clearance, we manipulated ARpolyQaggregation with two selective AR modulators, cyproterone
acetate and casodex. As previously shown, cyproterone acetate
induces ARpolyQ aggregates characterized by irregular shape,
and casodex does not cause ARpolyQ aggregation (Rusmini
et al., 2007). Interestingly, cyproterone acetate-induced ARpo-
lyQ aggregates have a much stronger capability to conﬁne p62
into bodies than the testosterone-induced ARpolyQ regular
spherical shape inclusions (Fig. 6F). Instead, when ARpolyQ
clearance was facilitated with casodex (Rusmini et al., 2007),
Fig. 8. Heat shock protein (Hsp)B8 and trehalose exert different activities on the autophagic removal of androgen receptor (AR) gene with an abnormally long polyglutamine tract
(ARpolyQ). (A) and (B) High resolution immunoﬂuorescence analysis of NSC34 cells transfected with GFP-AR.Q48, pCDNA3, or HspB8 in the absence (T) or in the presence (þT) of
10 nM of T for 48 hours, in basal condition or after treatment with 100 mM of trehalose for 48 hours. Nuclei were stained with DAPI (blue). Images obtained at magniﬁcation 63
(scale bar, 10 mm). Abbreviations: DAPI, 4,6-diamidino-2-phenylindole; pCDNA3, empty vector; T, testosterone.
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correlation between the kinetic of ARpolyQ aggregates forma-
tion and their limited clearance through the autophagic
pathway (Fig. 6F).Collectively, these data conﬁrm our hypothesis that HspB8
prevents ARpolyQ aggregation possibly by restoring its degradation
at earlier stages of the autophagic pathway (acting possibly via a
better target recognition).
Fig. 9. Trehalose induces heat shock protein (Hsp)B8 expression and both act in the autophagic clearance of mutant androgen receptor (AR) gene with an abnormally long
polyglutamine tract (ARpolyQ). (A) Real-time polymerase chain reaction of HspB8 mRNA expression levels on NSC34 cells expressing AR.Q46 in the absence (T) or in the presence
(þT) of 10 nM of T for 48 hours, in basal condition or after treatment with 100 mM of trehalose for 48 hours ( p < 0.01 vs. AR.Q46T). (B) Transcriptional activity assay of HspB8
promoter performed on NSC34 cells transfected with promB8 and pRL-TK, in basal condition or after treatment with 100 mM of trehalose for 48 hours (*** p < 0.001 vs. untreated
control). (C) Western blot analysis on cell lysates of NSC34 cells expressing AR.Q46 in the absence (T) or in the presence (þT) of 10 nM of T for 48 hours, in basal condition or after
treatment with 100 mM of trehalose for 48 hours. b-actin was used to normalize protein loading. (D) Filter retardation assay performed on NSC34 cells transfected with AR.Q46,
pCDNA3, or HspB8, in the absence (T) or in the presence (þT) of 10 nM of T for 48 hours, in basal condition or after treatment with 100 mM of trehalose for 48 hours (* p < 0.05 vs.
AR.Q46þT;  p < 0.05 vs. AR.Q46þTþtrehalose; # p < 0.05 vs. AR.Q46þTþHspB8). (E) Upper insets, Western blot analysis, and lower insets, ﬁlter retardation assay, on cell lysates of
NSC34 cotransfected with AR.Q46 and a small interfering RNA for endogenous HspB8 (SiRNA-HspB8) or its negative control (scramble). Cells were analyzed in the absence (T) or in
the presence (þT) of 10 nM of T for 48 hours, in basal condition or after treatment with 100 mM of trehalose for 48 hours. a-Tubulin was used to normalize protein loading (# p <
0.05 vs. scrambleþT,  p < 0.01 vs. scrambleþT;  p < 0.01 vs. SiRNA-HspB8þT). Abbreviations: mRNA, messenger RNA; NT, untransfected cells; pCDNA3, empty vector; pRL-TK,
renilla luciferase expression vector; promB8, ﬁreﬂy luciferase controlled by HspB8 promoter; SiRNA, small interfering RNA; T, testosterone.
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autophagic ARpolyQ clearance
Recent studies have provided convincing evidence that ARpolyQ
removal via autophagy can be beneﬁcial in SBMA (Montie and
Merry, 2009; Montie et al., 2009, 2011). Trehalose is an autopha-
gic activator used in these studies. Thus we wanted: (1) to compare
the effects of trehalose and HspB8; (2) to test whether these two
factors might act in a synergistic and/or additive manner; and (3)
evaluate whether trehalose might facilitate the autophagic process
by inducing HspB8 expression.We initially conﬁrmed that, in our NSC34 motoneuronal model
of SBMA, trehalose counteracts the testosterone-induced formation
of ARpolyQ (AR.Q46) insoluble species (Fig. 7A). In basal conditions,
trehalose almost doubled the amount of LC3 mRNA (Fig. 7B), and
HspB8 was ineffective on LC3 transcription. Thus, though trehalose
activates autophagy, HspB8 ameliorates the autophagic process but
does not activate autophagy. These data were then further
conﬁrmed bymeasuring endogenous LC3-I and LC3-II protein levels
in basal condition (nontransfected NSC34 cells). Fig. 7C shows that
trehalose increased the conversion of LC3-I to its lipidated, auto-
phagosome anchored, LC3-II, and HspB8 was not effective in this
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HspB8, induced a mild increase of the levels of endogenous LC3-II
and p62 proteins.
Then, we evaluated the trehalose effect on autophagy in the
presence of ARpolyQ and we found that in the absence or in the
presence of testosterone, trehalose increased mRNA levels of LC3
and p62 (Fig. 7D and E, respectively). Thus, the presence of a mutant
misfolded protein sensitizes cells to a greater autophagic activation
after trehalose treatment.
Finally, by blocking the autophagic pathway at very early stages
with 3-MA, we conﬁrmed that trehalose removes misfolded
ARpolyQ insoluble species via autophagy (Fig. 7F). In fact, we found
that 3-MA attenuates the effects of trehalose on the mutant AR,
because a large accumulation of insoluble ARpolyQ can be detected
in FRA in the presence of trehalose and 3-MA, and very low levels
were detectable in the presence of trehalose alone.
The data obtained by measuring LC3 mRNA and p62 mRNA
expression and protein levels were paralleled by their protein dis-
tribution (Fig. 8A and B, respectively). In fact, both autophagic
markers, LC3-II and p62 proteins, were found in a typical auto-
phagy-associated distribution (punctate LC3-II distribution and
disappearance of the ARpolyQ-induced p62 bodies). In agreement
with the molecular (real-time PCR) and biochemical data (WB),
trehalose induced a robust increase of LC3-II levels, further con-
ﬁrming that trehalose activates autophagy in immortalized moto-
neuronal cells (Fig. 8A).
We found also that trehalose increased HspB8 mRNA (Fig. 9A)
level. Moreover, taking advantage of the promB8 construct (Crippa
et al., 2010a, 2010b), in which HspB8 promoter drives luciferase
transcription, we demonstrated that trehalose effects on HspB8 are
exerted at transcriptional levels (Fig. 9B). This also resulted in
increased HspB8 protein level (Fig. 9C), suggesting that the auto-
phagic response to trehalose might also be potentiated by a facili-
tation of autophagy, mediated by HspB8. We thus evaluated
whether trehalose and HspB8 might act synergistically on the
removal of misfolded ARpolyQ, measuring total insoluble ARpolyQ
in FRA. The data (Fig. 9D) demonstrate that trehalose and HspB8
possess similar antiaggregation power on ARpolyQ, and their effects
on testosterone-induced insoluble ARpolyQ species are increased
when the 2 act together.
To evaluate whether HspB8 is involved in the pathways acti-
vated by trehalose to generate an increased autophagic response,
we silenced HspB8, and measured the amount of ARpolyQ-insol-
uble species still present after trehalose treatment. The data shown
in Fig. 9E conﬁrmed the importance of HspB8 in the removal of
testosterone-induced ARpolyQ-insoluble species (see also Fig. 1E).
HspB8 silencing in the presence of trehalose resulted in a signiﬁcant
increase of the accumulation of ARpolyQ (AR.Q46)-insoluble spe-
cies compared with trehalose alone. However, HspB8 silencing was
not sufﬁcient to completely abolish the prodegradative effects of
trehalose on ARpolyQ-insoluble species, suggesting that HspB8 is a
mediator, but not the only one, of the proautophagic activity of
trehalose.
4. Discussion
In the present study we investigated the effect of HspB8 on the
autophagic removal of the mutant ARpolyQ responsible for moto-
neuronal cell death in SBMA. In our immortalized motoneuronal
cells, used as an SBMA model, we conﬁrmed that ARpolyQ aggre-
gates only after testosterone treatment and speciﬁcally in cell
cytoplasm, as seen in some affected neuronal populations of SBMA
patients (Adachi et al., 2005; Suzuki et al., 2008). While, ARpolyQ
aggregation also occurs in the nuclei of cells from SBMA patients
(Katsuno et al., 2010;Walcott andMerry, 2002), we could not detectnuclear inclusions in our SBMAmodel (Rusmini et al., 2011). In fact,
reconstituting neuronal SBMA cell models with nuclear aggregates
require a very long polyQ tract (>100 contiguous Qs) (Montie et al.,
2009; Walcott and Merry, 2002). Indeed, ARpolyQ exerts its
neurotoxicity mainly at the nuclear level (even if independently
from inclusion formation), and cytoplasmic retention of ARpolyQ
has been found to preventmost of its adverse effects on cell survival
(Montie et al., 2009, 2011).
In our cells the levels of aberrant and/or potentially neurotoxic
misfolded species of ARpolyQ (induced by testosterone) cannot be
directly quantiﬁed. However, we took advantage of the fact that
misfolded species accumulate into “testosterone-induced aggre-
gates” and adopted aggregates as a “biomarker of ARpolyQ
misfolding.”
Our initial approach was to evaluate whether HspB8 alters
misfolded ARpolyQ dynamics. We found that HspB8 prevents the
formation of testosterone-induced ARpolyQ cytoplasmic aggregates
and facilitates ARpolyQ clearance from the cells. This clearance of
ARpolyQ does not require a fully functional proteasome system.
Silencing experiments have shown that the basal levels of HspB8
present in our cells are sufﬁcient to stimulate the removal of most,
but not all the misfolded ARpolyQ-insoluble species generated after
testosterone treatment. Interestingly, we also found that, in the
presence of ARpolyQ (either in absence or presence of testosterone;
thus, nontoxic vs. toxic conformation, respectively), the autophagic
process is already activated, because p62 and LC3 levels are
increased with LC3-II in its punctate, autophagosome-linked, dis-
tribution. Thus, cytoplasmic aggregates accumulation is indicative
of an incompleted autophagy, which can be associated with auto-
phagic ﬂux blockage. HspB8 facilitates the autophagy-mediated
degradation of the mutant ARpolyQ, possibly by enhancing its
recognition. Notably, when autophagy is pharmacologically or
genetically blocked, HspB8 cannot assist ARpolyQ degradation.
Thus, by preventing misfolded ARpolyQ accumulation, HspB8
might indirectly restore the autophagic ﬂux to physiological level.
HspB8 alone does not induce LC3 mRNA (and p62 mRNA, not
shown) expression, and is unable to activate LC3 conversion to its
lipidated, autophagosome-anchored LC3-II, 2 steps required for
autophagy activation. Therefore, in our motoneuronal cells, HspB8
does not trigger autophagy, but it ameliorates the already activated
autophagic process. In fact, others and we recently demonstrated
that, in motoneuronal cells, HspB8 not only associated with its
natural cochaperone BAG-3 (Carra et al., 2008a, 2008b), but also
interacts (when bound to BAG-3) with Hsc70 and CHIP. This het-
eromeric complex is required to allow the CHIP-mediated ubiqui-
nation of the targetmisfolded substrates (Crippa et al., 2010b). CHIP
dysfunction has also been reported in SBMA (and in amyotrophic
lateral sclerosis [ALS]) and its overexpression has a beneﬁcial effect
in both diseases (Morishima et al., 2008). Similar observations have
been reported for the other members of the hetero-complex, Hsc70
(Urushitani et al., 2004; Wang et al., 2009), or Hsp70 (Adachi et al.,
2003; Kobayashi et al., 2000; Warrick et al., 1999; Waza et al., 2005,
2006). The same multiheteromeric complex has been found in
muscle (Arndt et al., 2010), where it serves for the recognition of
proteins damaged (misfolded) during prolonged physical exercise.
It is of note that ARpolyQ might exert toxicity also at the muscle
level (Adachi et al., 2007; Arndt et al., 2010; Cardozo et al., 2003;
Jana et al., 2005; Johansen et al., 2009; Miller et al., 2005; Mo
et al., 2010; Urushitani et al., 2004; Yu et al., 2011). When the
substrate is ubiquitinated by CHIP, within the HspB8/BAG-3/Hsc70/
CHIP complex, the misfolded protein can be released and recog-
nized by p62 for its insertion into autophagosomes (Carra et al.,
2012). The importance of cytoplasmic recognition and autophagic
clearance of ARpolyQ to prevent its nuclear neurotoxicity has
already been clearly established by other investigators (Montie and
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model of the HspB8 mechanism of action, the mutant ARpolyQ has
to be recognized in its misfolded fraction, after its release from
accessory proteins (HSP70, HSP90, etc.) during the activation pro-
cess (triggered by testosterone) (Poletti, 2004; Rusmini et al., 2007).
Thus, once recognized by HspB8, the misfolded ARpolyQ will be
rerouted from aggregation (and possibly from proteasomal degra-
dation) to the “ubiquitination complex” of BAG-3, Hsc70, and CHIP,
recognized by p62 and then released to the autophagic pathway.
We found a close association of ARpolyQ aggregates with the p62
bodies, but not p62 sequestration; we did not ﬁnd ARpolyQ ag-
gregates that colocalized with (or were surrounded and/or
entrapped by) LC3-II. Instead, LC3eII-positive/ARpolyQ-negative
autophagosomes accumulate in cells. Collectively, these data indi-
cate that autophagic ﬂux alterations occur at very early stages,
possibly during cytoplasmic misfolded protein recognition, but
before the ARpolyQ insertion into the autophagosomes. In fact,
during basal autophagy activation, p62 is mainly diffused and
shows an elevated turnover. Instead, with defective autophagy (i.e.,
linked to impairment in cargo delivery or autophagic ﬂux blockage),
p62 polymerizes, accumulates, and aggregates into Triton Xe100-
insoluble p62 bodies (Mizushima and Komatsu, 2011). Notably,
these bodies enhances alternative p62 functions to act as a scaffold
protein in several signaling pathways (Matsumoto et al., 2011;
Mizushima and Komatsu, 2011), that are crucial for the cell
response to protein toxicity and also known to be able to trigger
deleterious pathways for neuronal cells (Matsumoto et al., 2011;
Mizushima and Komatsu, 2011). The data presented here clearly
demonstrate that the overexpression of HspB8, either by facilitating
the ARpolyQ recognition, or its ubiquitination by CHIP (or even the
acquisition of a particular conformation more suitable for the
interaction with the ubiquitination complex), prevents the p62
bodies formation (and thus their potential neurotoxicity) and the
LC3-II accumulation in large (potentially deleterious) excess,
allowing the complete removal of misfolded ARpolyQ via an auto-
phagic ﬂux restored to its physiological level. In addition, this
“cytoplasmic” activity of HspB8 will prevent the migration of mis-
folded ARpolyQ species into the nuclei, where they can exert their
neurotoxicity. So far, there is no evidence that HspB8 can exert ef-
fects in the nucleus, even if the protein is also localized in this
intracellular compartment.
In a parallel study, we compared the effect of HspB8 on
ARpolyQs with different polyQ sizes (Q46 and Q112), which
aggregate in different cellular compartments in SBMA cell models.
Indeed though AR.Q46 shows cytoplasmic aggregation, AR.Q112
shows nuclear aggregation. In that study we found that HspB8 is
much less active in the removal of insoluble species generated by
AR.Q112 than by AR.Q46 (Carra et al., 2013). Though aggregate
localization (nuclear vs. cytoplasmic) might be involved in this
selective sensitivity of HspB8 against the 2 ARpolyQs, it is also
possible that particular AR.Q112 aggregate structures (or their
faster kinetic of formation) make them less sensitive to the pro-
degradative activity of HspB8. Unfortunately, this observation
might have a relevant implication in the attempt to conﬁrm the
beneﬁcial effects of HspB8 in SBMA animal models. In fact, all
transgenic (tg) SBMA mice showing neurological signs and pres-
ently available, bear a very long CAG stretch, coding for polyQ
tracts of at least 97 Qs (Adachi et al., 2003; Chevalier-Larsen et al.,
2004; Katsuno et al., 2003a, 2003b; La Spada et al., 1998; Li et al.,
2007; Lieberman and Robins, 2008; Yu et al., 2006). This tract has
never been found in patients, and might be more similar to that
usually found in the huntingtin mutant protein associated with
juvenile forms of Huntington disease, which are clinically distinct
(and possibly have a different molecular basis of toxicity) from the
forms found in older patients associated with shorter, but stillpathological tracts (polyQs ranging from 36 to 60) (Martindale
et al., 1998).
Previous studies performed in our lab, already showed that in
spinal cord motoneurons that survive at the end stage of disease in
transgenic ALS mice (Crippa et al., 2010a, 2010b), HspB8 is
expressed at very high levels. Similar data have been obtained in
spinal cord of ALS patients (Anagnostou et al., 2010). Finally, pre-
liminary results obtained in our laboratory suggest that HspB8
expression is also increased at later stages of disease in the spinal
cord of transgenic SBMA mice (knock-in mice developed by Prof
Andrew Lieberman) (Jordan and Lieberman, 2008; Yu et al., 2006)
(Rusmini et al, unpublished observation). Therefore, on the basis of
the HspB8 mechanism of action proposed here, it is possible that
HspB8 plays a protective role in affected motoneurons by facili-
tating the clearance of potentially neurotoxic misfolded proteins. It
would be of great interest to ﬁnd pharmacological approaches to
overinduce HspB8 expression in motoneurons of affected in-
dividuals before appearance of symptoms. By analyzing the acti-
vation of the HspB8 promoter we found that it is positively
regulated by proteasome inhibition (data conﬁrmed also by WB
analysis), a condition paralleled by a compensatory autophagy
activation and triggered by misfolded proteins causative of neuro-
degenerative diseases (Crippa et al., 2010a, 2010b). This evidence
correlates with the desaturation of UPS observed when HspB8 is
expressed in the presence of nonactivated ARpolyQ (AR.Q46
without testosterone). However, as mentioned earlier in text,
HspB8 does not directly trigger autophagy, therefore other rerout-
ing mechanisms and/or proteins should be involved in the speciﬁc
degradative pathways selected for the intracellular clearance of
misfolded proteins (i.e., BAG-3). It must also be noted that the
prodegradative and/or antiaggregation activity of HspB8 is also
detectable using other protein prone to misfold and linked to
different neurodegenerative diseases (Carra et al., 2005; Crippa
et al., 2010a, 2010b).
Interestingly, our data are in line with very recent observations
obtained in tg mice models of SBMA. In fact, the alteration of the
overall chaperone response, obtained by knocking down HSF-1
expression in tg SBMA mice resulted in increased symptomatology
and the involvement of structures normally unaffected in SBMA
(Kondo et al., 2013). In contrast, overexpression of the Hsp70
interacting protein, which increases the Hsp70 substrate interac-
tion, induces ARpolyQ clearance (Wang et al., 2013). Interestingly, it
has recently been reported that a synthetic cochaperone mimicking
Hsp70 interacting protein activity alleviates ARpolyQ toxicity in a
SBMA Drosophilamodel (Wang et al., 2013). Moreover, upregulation
or stimulation of the chaperone response, and of the mediators of
autophagy involved in HspB8 activity (i.e., CHIP) ameliorates the
symptomatology in the same tg SBMA mice models (Adachi et al.,
2003, 2007; Carra et al., 2013; Katsuno et al., 2005; Kobayashi
and Sobue, 2001; Kobayashi et al., 2000; Tokui et al., 2009; Waza
et al., 2005, 2006). Finally, arimoclomol, a coinducer of the heat
shock stress response, administered orally to tg SBMA mice
signiﬁcantly improved hind limb muscle force and contractile
characteristics, rescuing motor units. Arimoclomol treatment also
resulted in improved motor neuron survival, with increased
expression of VEGF, an important neurotrophic factor. Thus is well
accepted that heat shock response activation might have relevant
therapeutic implications in SBMA (Malik et al., 2013).
We also analyzed the activity of the autophagy inducer, treha-
lose, which has been shown to be beneﬁcial in SBMA (Montie and
Merry, 2009; Montie et al., 2009, 2011) and other types of neuro-
degenerative diseases (Lan et al., 2012). Trehalose induced the LC3
expression and promoted the LC3-II formation in our immortalized
motoneuronal cells, conﬁrming that it activates autophagy. Inter-
estingly, we found that trehalose increased the endogenous levels
P. Rusmini et al. / Neurobiology of Aging 34 (2013) 2585e26032600of HspB8 in motoneuronal cells activating the HspB8 promoter.
These data suggest that the proautophagic activity of trehalose on
ARpolyQ might also require HspB8 activation, even if silencing ex-
periments have shown that HspB8 is a mediator, but not the only
one involved in the proautophagic activity of trehalose. Hovewer,
the two factors act synergistically in the removal of ARpolyQ-
insoluble species induced by testosterone, indicating that potential
therapeutic approaches to counteract ARpolyQ neurotoxicity in
SBMAmust taken into account in the possibility of using cocktails of
drugs that might interfere with different steps of the pathogenic
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